CD8A and neoplasm: In all of the tumor cell lines, nivolumab induced a decrease of CD8+ Tn and an increase of activated CD8+ T cells in either PB or spleen, or both in huNOG-FcγR−/− mice, TEM for HSC4, NCI-H1975, and RKO or TCM for HCC827 (Fig. 8, Supplementary Figs. 12, 13).